Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
29 pending office actions • 15 clients • 26 examiners • 16 art units • 0 of 29 (0%) have an AI response strategy ready
LICATA & TYRRELL P.C. has a history in Biotechnology & Pharmaceuticals, having managed 2260 career applications. The firm maintains a resolved allowance rate of 68.07 percent. Prosecution in these areas involves an average of 4.3 office actions per allowance, which reflects the negotiation and iterative process required to reach a final disposition for biotech and pharmaceutical inventions. These figures provide a record of the firm's historical performance across its total filings.
The firm is currently managing 22 pending office actions. This volume of active work, alongside the 2260 career applications, indicates the firm's practice. The 68.07 percent allowance rate serves as a baseline for the firm's success, while the 4.3 average office actions per allowance helps practitioners estimate the effort required for each application. These data points together illustrate the firm's experience and current capacity within its primary technology area. This analysis offers a grounded view of the firm's prosecution profile.
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (10%) |
| §103 only | 8 (28%) |
| §102 only | 1 (3%) |
| §112 only | 3 (10%) |
| Double-patenting + other | 7 (24%) |
| Multi-statute (no §101) | 7 (24%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COFFA, SERGIO | 2 | 61.1% | +32.5% |
| LU, CHENG | 2 | 54.1% | +64.1% |
| HUYNH, PHUONG N | 2 | 65.7% | +53.6% |
| BOECKELMAN, JACOB A | 1 | 35.2% | +45.6% |
| CAIN, JENNIFER LYNN | 1 | 45.0% | +70.0% |
| PAK, MICHAEL D | 1 | 58.3% | +30.4% |
| HWU, JUNE | 1 | 91.3% | -2.0% |
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
| MOLOYE, TITILAYO | 1 | 62.5% | +47.9% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18633283 | N-Terminal Capping Modules of Ankyrin Repeat Domains | COFFA, SERGIO | 86d overdue |
| 18268032 | BURKHOLDERIA VACCINES AND THERAPEUTICS | MORGAN, BAILEY MICHELLE | 14d |
| 17923070 | Hypoimmunogenic Cells and Uses Thereof in Immune Responses | HUYNH, PHUONG N | 34d |
| 17919622 | SYSTEM AND METHOD FOR MICRODIALYSIS FOR IN-VITRO RELEASE TESTING OF DOSAGE FORMS | HERBERT, MADISON TAYLOR | 34d |
| 19065181 | STEM CELL-SPECIFIC PROMOTER FROM SACCHARUM AND METHODS FOR INCREASING FATTY ACID AND/OR OIL ACCUMULATION | HWU, JUNE | — |
| 18805952 | BROCCOLI EXTRACT, NUTRACEUTICAL, AND METHODS OF TREATING INFLAMMATION AND CANCER | FIEBIG, RUSSELL G | — |
| 18723927 | NONHUMAN STEM CELLS AND THEIR USE FOR PRODUCTION OF CULTURED MEAT | MOLOYE, TITILAYO | — |
| 18427042 | METHOD OF USING PACAP AND VIP PEPTIDES FOR DETECTING SHED OR CIRCULATING TUMOR CELLS IN BIOLOGICAL FLUIDS | LU, CHENG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18633283 | N-Terminal Capping Modules of Ankyrin Repeat Domains | COFFA, SERGIO | 86d overdue |
| 17778138 | PENTAPEPTIDE AND METHODS OF USE THEREOF | COFFA, SERGIO | 28d |
| 17923070 | Hypoimmunogenic Cells and Uses Thereof in Immune Responses | HUYNH, PHUONG N | 34d |
| 19558906 | METHODS AND COMPOSITIONS FOR REDUCING MUSCLE LOSS AND/OR INHIBITING SARCOPENIA ASSOCIATED WITH WEIGHT LOSS | BOECKELMAN, JACOB A | — |
| 19413266 | Methods and Compositions for Managing and/or Alleviating Symptoms of Muscular Dystrophies and Other Genetic Muscular Disorders | CAIN, JENNIFER LYNN | — |
| 19363223 | ELUATE COLLECTION DURING ANTIBODY CHROMATOGRAPHY | PAK, MICHAEL D | — |
| 18805952 | BROCCOLI EXTRACT, NUTRACEUTICAL, AND METHODS OF TREATING INFLAMMATION AND CANCER | FIEBIG, RUSSELL G | — |
| 18723927 | NONHUMAN STEM CELLS AND THEIR USE FOR PRODUCTION OF CULTURED MEAT | MOLOYE, TITILAYO | — |
| Client (Assignee) | Pending OAs |
|---|---|
| University of Illinois | 7 |
| Novartis | 3 |
| University of Hawaii | 3 |
| MYOS | 2 |
| Athebio AG | 2 |
| St. Jude Children's Research Hospital Inc. | 2 |
| RXCELL INC. | 2 |
| Atelier Meats Corp. | 1 |
| Dartmouth College | 1 |
| THOMAS JEFFERSON UNIVERSITY | 1 |
| Pai Life Sciences Inc. | 1 |
| ProVEDA Corporation | 1 |
| WASHINGTON UNIVERSITY | 1 |
| ORTIV-Q3 RESEARCH PVT. LTD | 1 |
| WELLNAS.CO., LTD | 1 |
| Art Unit | Apps |
|---|---|
| 1645 | 3 |
| 1655 | 2 |
| 1658 | 2 |
| 1626 | 2 |
| 1633 | 2 |
| 1674 | 1 |
| 1661 | 1 |
| 1614 | 1 |
| 1642 | 1 |
| 1647 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19558906 | METHODS AND COMPOSITIONS FOR REDUCING MUSCLE LOSS AND/OR INHIBITING SARCOPENIA ASSOCIATED WITH WEIGHT LOSS | Myos Corp. | BOECKELMAN, JACOB A | 1655 | §103§112DP | Final Rejection | — | Pending | Mar 06, 2026 |
| 19413266 | Methods and Compositions for Managing and/or Alleviating Symptoms of Muscular Dystrophies and Other Genetic Muscular Disorders | Myos Corp. | CAIN, JENNIFER LYNN | 1655 | §102§103§112DP | Final Rejection | — | Pending | Dec 09, 2025 |
| 19363223 | ELUATE COLLECTION DURING ANTIBODY CHROMATOGRAPHY | Morphosys GmbH | PAK, MICHAEL D | 1674 | §112DP | Final Rejection | — | Pending | Oct 20, 2025 |
| 19065181 | STEM CELL-SPECIFIC PROMOTER FROM SACCHARUM AND METHODS FOR INCREASING FATTY ACID AND/OR OIL ACCUMULATION | The Board Of Trustees Of The University Of Illinois | HWU, JUNE | 1661 | §103§112 | Non-Final OA | — | Pending | Feb 27, 2025 |
| 18805952 | BROCCOLI EXTRACT, NUTRACEUTICAL, AND METHODS OF TREATING INFLAMMATION AND CANCER | The Board Of Trustees Of The University Of Illinois | FIEBIG, RUSSELL G | §101§103§112 | Non-Final OA | — | Pending | Aug 15, 2024 | |
| 18723927 | NONHUMAN STEM CELLS AND THEIR USE FOR PRODUCTION OF CULTURED MEAT | Atelier Meats Corp. | MOLOYE, TITILAYO | §103§112 | Non-Final OA | — | Pending | Jun 25, 2024 | |
| 18706257 | TRANSPOSABLE MOBILE ELEMENTS WITH ENHANCED GENOMIC SITE SELECTION | UNIVERSITY OF HAWAII | VANHORN, ABIGAIL LOUISE | §102§103§112DP | Non-Final OA | — | Pending | Apr 30, 2024 | |
| 18633283 | N-Terminal Capping Modules of Ankyrin Repeat Domains | Athebio AG | COFFA, SERGIO | 1658 | §102§103§112 | Non-Final OA | 86d overdue | Pending | Apr 11, 2024 |
| 18599832 | METHOD FOR ATTENUATING NEUROINFLAMMATION, AMYLOIDOPATHY AND TAUOPATHY | The Trustees of Dartmouth College | COUGHLIN, MATTHEW P | 1626 | §103§112DP | Final Rejection | — | Pending | Mar 08, 2024 |
| 18442492 | Variants of Ankyrin Repeat Domains | Athebio AG | TSUI, YUNG-SHENG M | §112DP | Non-Final OA | — | Pending | Feb 15, 2024 | |
| 18427042 | METHOD OF USING PACAP AND VIP PEPTIDES FOR DETECTING SHED OR CIRCULATING TUMOR CELLS IN BIOLOGICAL FLUIDS | Thomas Jefferson University | LU, CHENG | §101§112DP | Non-Final OA | — | Pending | Jan 30, 2024 | |
| 18291283 | COMBINATIONS OF ANTIGEN BINDING MOLECULES | Morphosys GmbH | HUYNH, PHUONG N | §112Other | Non-Final OA | — | Pending | Jan 23, 2024 | |
| 18567159 | PHOTOACTIVATABLE GASDERMIN PROTEINS | The Board Of Trustees Of The University Of Illinois | STOICA, ELLY GERALD | §102§112 | Non-Final OA | — | Pending | Dec 05, 2023 | |
| 18275463 | VACCINE AND METHODS FOR PREVENTING FILARIASIS AND DIROFILARIASIS | Pai Life Sciences Inc. | GANGLE, BRIAN J | 1645 | §112 | Final Rejection | 48d | Pending | Aug 02, 2023 |
| 18268032 | BURKHOLDERIA VACCINES AND THERAPEUTICS | UNIVERSITY OF HAWAII | MORGAN, BAILEY MICHELLE | 1645 | §101§102 | Final Rejection | 14d | Pending | Jun 16, 2023 |
| 18307253 | TOPICAL FORMULATIONS | Proveda Corporation | KETCHAM, KAREN A | 1614 | §103 | Final Rejection | 139d overdue | Pending | Apr 26, 2023 |
| 18246052 | NOVEL HUMAN ANTIBODIES BINDING TO HUMAN CD3 EPSILON | Morphosys GmbH | LU, CHENG | 1642 | §112 | Non-Final OA | — | Pending | Mar 21, 2023 |
| 18245257 | METHODS FOR TREATING OR MODULATING AN INFLAMMATORY RESPONSE | St. Jude Children's Research Hospital | LANDSMAN, ROBERT S | 1647 | §103 | Final Rejection | 24d overdue | Pending | Mar 14, 2023 |
| 18178736 | METHODS AND MICROFLUIDIC DEVICE FOR PRODUCING EXTRACELLULAR VESICLES | The Board Of Trustees Of The University Of Illinois | SPENCE, JENNIFER SUZANNE | 1633 | §103 | Non-Final OA | 23d | Pending | Mar 06, 2023 |
| 18043095 | ALGINATE-COATED MESENCHYMAL STROMAL AND PROGENITOR CELLS AND METHODS FOR USING THE SAME | The Board Of Trustees Of The University Of Illinois | CONNORS, ALEXANDRA F | 1634 | §103 | Final Rejection | — | Pending | Feb 27, 2023 |
| 18042015 | COMPOSITIONS AND METHOD FOR TREATING THALASSEMIA | St. Jude Children's Research Hospital | WHITEMAN, BRIAN A | 1636 | §103 | Final Rejection | 2d overdue | Pending | Feb 17, 2023 |
| 17923070 | Hypoimmunogenic Cells and Uses Thereof in Immune Responses | Rxcell Inc. | HUYNH, PHUONG N | 1641 | §102§103§112Other | Non-Final OA | 34d | Pending | Nov 03, 2022 |
| 17923029 | METHODS FOR TREATING OR REDUCING THE SEVERITY OF A VIRAL INFECTION | Washington University | BELYAVSKYI, MICHAIL A | 1644 | §103 | Non-Final OA | 105d overdue | Pending | Nov 03, 2022 |
| 17919622 | SYSTEM AND METHOD FOR MICRODIALYSIS FOR IN-VITRO RELEASE TESTING OF DOSAGE FORMS | Ortiv-Q3 Research Pvt. Ltd. | HERBERT, MADISON TAYLOR | 1758 | §103§112 | Non-Final OA | 34d | Pending | Oct 18, 2022 |
| 17913535 | Hypoimmunogenic Cells and Methods and Compositions for Their Production | Rxcell Inc. | GU, QINHUA | 1633 | §103 | Final Rejection | — | Pending | Sep 22, 2022 |
| 17750968 | VACCINE AND METHODS FOR DETECTING AND PREVENTING FILARIASIS | The Board Of Trustees Of The University Of Illinois | ZEMAN, ROBERT A | 1645 | §103§112Other | Non-Final OA | — | Pending | May 23, 2022 |
| 17778138 | PENTAPEPTIDE AND METHODS OF USE THEREOF | The Board Of Trustees Of The University Of Illinois | COFFA, SERGIO | 1658 | §102 | Non-Final OA | 28d | Pending | May 19, 2022 |
| 17774723 | Method for Preparing Heteroleptic Triarylbismuthanes and Compounds Produced by the Same | UNIVERSITY OF HAWAII | CHENG, KAREN | 1623 | §103 | Non-Final OA | 43d overdue | Pending | May 05, 2022 |
| 17433900 | ORALLY INGESTED COMPOSITION FOR IMPROVING SLEEP | Wellnas.Co., Ltd. | CHICKS, ASHLI ARIANA | 1626 | §103DP | Final Rejection | — | Pending | Aug 25, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial